Skip to main content
Clinical Trials/EUCTR2018-003416-50-DK
EUCTR2018-003416-50-DK
Active, not recruiting
Phase 1

Prevention of breast cancer-related lymphedema with tacrolimus

Odense University Hospital0 sites40 target enrollmentOctober 3, 2018

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
ymphedema
Sponsor
Odense University Hospital
Enrollment
40
Status
Active, not recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 3, 2018
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
Female

Investigators

Eligibility Criteria

Inclusion Criteria

  • Diagnosticeret med brystkræft og skal have fjernet samtlige lymfeknuder i armhulen ved operation, som led i kræftbehandlingen.
  • Indikationen for fjernelse af alle lymfeknuder i armhulen.
  • Alder mellem 18\-75 år
  • Postmopausal (udebleven menstruation i min. 12 mdr.) eller kontinuerligt brug af svangerskabsforebyggende midler (Spiral, p\-piller, implantat, transdermal depotplastre, vaginalring eller depotinjektion)
  • God almentilstand (ASA score 1 eller 2\)
  • Modsatte arm er normal (intet lymfødem)
  • Forstår undersøgelsens formål og natur og giver skriftligt informeret samtykke.
  • Kan læse og forstå dansk.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:

Exclusion Criteria

  • Pregnant, breastfeeding or wishing to conceive within the next year.
  • Bilateral breast cancer
  • Known allergy to Tacrolimus or the macrolide type antibiotics.
  • Removal of lymph nodes from the opposite armpit.
  • Known lymphedema in parallel or opposite arm
  • Other malignant disease in addition to breast cancer (non\-melanoma skin cancer)
  • In medical treatment for diabetes mellitus.
  • Known with psychiatric disorder that may influence participation in the study.
  • Known with poor renal or hepatic function.

Outcomes

Primary Outcomes

Not specified

Similar Trials